FDA Guides Faster Path for Generic Drug Approvals
Published Date: 6/16/2025
Notice
Summary
The FDA just released new rules to help generic drug makers send important info about their factories before submitting priority drug applications. This speeds up reviews and helps the FDA set clear goals for fast-tracking these drugs. If you’re in the generic drug business, get ready to share your facility details early to keep things moving smoothly and meet new deadlines tied to the latest fee program.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Send Factory Details Before Priority ANDAs
The FDA's final guidance explains what facility information generic drug makers must send in a pre-submission facility correspondence (PFC) before filing a prioritized Abbreviated New Drug Application (ANDA). The guidance explains how FDA will use that facility information to set a review goal for a priority ANDA.
Guidance Implements GDUFA III Enhancement
The guidance incorporates a program enhancement agreed between FDA and industry as part of the Generic Drug User Fee Amendments (GDUFA) reauthorization and described in the GDUFA III commitment letter for Fiscal Years 2023-2027. The document finalizes the draft guidance that was issued on December 5, 2022.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-10921, Government-Owned Inventions; Availability for Licensing
The U.S. Government owns some cool inventions and is ready to license them out so companies can bring them to market faster. This means businesses can grab rights to use these inventions, including some with international patent protection. If you’re a company looking to innovate, now’s the time to check out these opportunities and get in on the action!
Next: 2025-10923, Applications for Membership to the American Fisheries Advisory Committee
The Secretary of Commerce is looking for 7 new members to join the American Fisheries Advisory Committee, which helps guide fishing policies. If you love fish and want to make a difference, now’s your chance! Members will serve for three years, so get ready to dive into some important work soon.